K. Hartemink

Proteomics of human cancer-associated T cells identifies regulators of T cell functionality

Kaspar Bresser, Žan Hozjan, Nila H. Servaas, Suzan Stelloo et autres

Abstract CD8⁺ T cells in solid cancers progressively lose anti-tumor activity, yet the cell-intrinsic mechanisms driving this loss of function remain incompletely defined. Here, we performed matched proteomic and transcriptomic profiling of dysfunctional and bystander CD8⁺ tumor-infiltrating T cells isolated from primary …

nl (code pays fourni par la source)

Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)

Kristof Cuppens, Marcel Wiesweg, Brigitte Maes, Bert Du Pont et autres

BACKGROUND: Preoperative immunotherapy targeting PD-1/-L1 with chemotherapy induces histopathological responses and improves survival in patients with resectable non-small cell lung cancer (NSCLC). NEOpredict-Lung (NCT04205552) established the feasibility of dual blockade of PD-1 and LAG-3 immune checkpoints prior to curatively intended resection. Here …

be, de, nl (code pays fourni par la source)

OA01.05 Neoadjuvant Nivolumab with or without Relatlimab in Resectable NSCLC: Additional Analysis and Extended Follow-up

Kristof Cuppens, M. Wiesweg, Bert Du Pont, Till Ploenes et autres

be, nl, de, at (code pays fourni par la source)

LBA37 A randomized, multicentric phase II study of preoperative nivolumab plus relatlimab or nivolumab in patients with resectable non-small cell lung cancer (NEOpredict-Lung)

M.H.H. Schuler, K. Cuppens, T. Ploenes, M. Vanbockrijck et autres

de, be, nl (code pays fourni par la source)